Clinical trial · Interventional
Pilot Study of PACHA Program to Enhance Adherence to Adjuvant Endocrine Therapy Among Breast Cancer Survivors
Pilot Study of a Community Pharmacy-Based Program to Enhance Adherence to Adjuvant Endocrine Therapy Among Breast Cancer Survivors
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this randomized controlled pilot study is to assess the feasibility, acceptability, and preliminary effects of the PACHA program designed for women having an adjuvant endocrine therapy (AET) after hormone-sensitive breast cancer. PACHA (programme en Pharmacie pour l'ACcompagnement des femmes ayant de l'Hormonothérapie Adjuvante) is a community pharmacy-based program aimed at optimizing the experience of AET and its use. The main questions it aims to answer are : * Does the program have an effect on factors expected to influence AET adherence? * Is the program acceptable? * Is the implementation of the program feasible? * What is the feasibility of procedures for carrying out a full-scale study? Participating community pharmacies will be randomized. Pharmacists working in pharmacies assigned to the PACHA group (33 pharmacies) will receive web-based training and manuals to use during their consultations with women having an AET. Recruited women attending these pharmacies will also have access to information and resources about AET (videos, evidence-based booklet). Pharmacists practicing in pharmacies assigned to the control group (33 pharmacies) will provide usual care.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Breast Neoplasms | Breast Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| PACHA Program | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- PACHA program group
- description
- Pharmacists and women in the PACHA program group will receive the PACHA program component's.
- interventionNames
- Behavioral: PACHA Program
- type
- NO_INTERVENTION
- label
- Usual care group
- description
- Pharmacists and women in the Usual care group will provide/receive usual care.
Primary outcomes (17)
- measure
- Mean change from baseline to the end of 6-month follow-up in intention to adhere to adjuvant endocrine therapy
- timeFrame
- Baseline and 6-month post-randomisation
- description
- Measured by a questionnaire developed and validated by our team (4 items, score range: 1-7), higher score means higher intention to adhere
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: For pharmacies : * In the province of Quebec, Canada * At least one pharmacist agrees to take charge of the project in their pharmacy * At least one women has initiated adjuvant endocrine therapy (AET) in the last 6 months in the pharmacy For pharmacists : * Practicing in a pharmacy in the province of Quebec * Provide consent For women : * 18 years old or older * Were diagnosed with a first non-metastatic, hormone-sensitive breast cancer * Received and AET prescription for the first time in the last 6 months * Are fluent in French * Have internet access * Provide consent Exclusion Criteria: For women : • Live in a residential facility where AET is not self-managed
References
Publications (1)
- DERIVEDLapointe J, Guillaumie L, Dionne A, Lalonde L, Lemieux J, Dorval M, Nabi H, Lemay M, Guenette L, Guertin JR, Masse B, Lauzier S. A community pharmacy-based program to enhance adherence to adjuvant endocrine therapy among breast cancer survivors (PACHA): protocol for a pilot cluster-randomized controlled trial. Pilot Feasibility Stud. 2025 Jul 14;11(1):98. doi: 10.1186/s40814-025-01676-8. PMID 40660375